Tag results:

lung cancer

Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET

[Cancer Research] Researchers identified that loss of an epigenetic factor, lysine methyltransferase 5C (KMT5C), drove resistance of NSCLC to multiple EGFR inhibitors, including erlotinib, gefitinib, afatinib, and osimertinib.

Single-Cell Analysis of Somatic Mutations in Human Bronchial Epithelial Cells in Relation to Aging and Smoking

[Nature Genetics] Scientists applied single-cell whole-genome sequencing of proximal bronchial basal cells from 33 participants aged between 11 and 86 years with smoking histories varying from never-smoking to 116 pack-years.

Long Noncoding RNA SH3PXD2A-AS1 Promotes NSCLC Proliferation and Accelerates Cell Cycle Progression by Interacting with DHX9

[Cell Death Discovery] The authors found that SH3PXD2A-AS1 expression in NSCLC tissues was upregulated compared with that in normal lung tissues in The Cancer Genome Atlas database by using the GEPIA website.

IO Biotech Announces Initiation of Phase II Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

IO Biotech Announces Initiation of Phase II Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

Janssen Announces Health Canada Approval of RYBREVANT® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon...

[Janssen Pharmaceutical Companies] The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has issued a Notice of Compliance with Conditions approving RYBREVANT®, a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic NSCLC.

Popular